News

Sarepta Therapeutics Inc. (NASDAQ:SRPT) is a commercial-stage biopharmaceutical company that discovers and develops ...
Del-zota is designed for patients with mutations amenable to exon 44 skipping, which is just 7% of the overall DMD patient ...
The manufacturing-related rejection for UX111 is more than a setback for Ultragenyx, as it also delays a key test of the new ...
Solid Biosciences' DMD gene therapy shows promise with SGT-003 and strong cash backing through 2027. Click here to read an ...
The company said it was optimistic that the issues identified by the Food and Drug Administration could be resolved with new data.
A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...
The company said it was “surprised” by the decision, which followed the ouster of cell and gene therapy officials from the ...
The FDA told Capricor in a letter that it is unable to approve its application for Deramiocel in its current form as it does ...
TAS-205 showed no significant impact on motor function in patients with Duchenne muscular dystrophy (DMD), highlighting the ongoing search for effective treatments for the rare condition.
The U.S. Food and Drug Administration has declined to approve Capricor Therapeutics' cell therapy for a heart condition and ...
Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.
ICER’s upcoming report could shed light on how the launch price of newly approved drugs affects overall cost and access from ...